ZX008 (Fenfluramine Hydrochloride)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome
Trial Timeline
Jun 8, 2016 → Jan 27, 2023
NCT ID
NCT02823145About ZX008 (Fenfluramine Hydrochloride)
ZX008 (Fenfluramine Hydrochloride) is a phase 3 stage product being developed by UCB for Dravet Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02823145. Target conditions include Dravet Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03936777 | Phase 3 | Completed |
| NCT03299842 | Phase 3 | Terminated |
| NCT02823145 | Phase 3 | Completed |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 30 |
| fenfluramine | UCB | Approved | 82 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 20 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| fenfluramine | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 82 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 72 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 36 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 47 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |